Video

Dr. Lallas on Challenges With Immunotherapy in Genitourinary Malignancies

Author(s):

Costas Lallas, MD

In Partnership With:

Costas Lallas, MD, professor at Sidney Kimmel Medical College, Thomas Jefferson University Hospital, discusses challenges with immunotherapy in genitourinary (GU) malignancies.

Costas Lallas, MD, professor at Sidney Kimmel Medical College, Thomas Jefferson University Hospital, discusses challenges with immunotherapy in genitourinary (GU) malignancies.

Most checkpoint inhibitors in GU cancers are still relatively new, says Lallas. Physicians want to be sure that they are giving the patients what they believe to be the best treatment, but as of now there is not a lot of information regarding immunotherapy in these diseases.

Additionally, the cost of these agents is very high, says Lallas, but as more positive data and knowledge about immunotherapy comes out in this disease, the cost may become more reasonable.

Related Videos
Arndt Vogel, MD
Suresh S. Ramalingam, MD, FACP, FASCO, professor, Department of Hematology and Medical Oncology, Roberto C. Goizueta Distinguished Chair for Cancer Research, Emory University School of Medicine, executive director, Winship Cancer Institute of Emory University, associate vice president, cancer, Woodruff Health Sciences Center
Byoung Chol Cho, MD, PhD, professor, internal medicine, Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine
Stephen J. Freedland, MD
Viktor Grünwald, MD, PhD
Aaron Gerds, MD
Christine M. Lovly, MD, PhD, Ingram Associate Professor of Cancer Research, associate professor, medicine (hematology/oncology), Vanderbilt-Ingram Cancer Center
Haeseong Park, MD, MPH
David L. Porter, MD
Timothy Yap, MBBS, PhD, FRCP
Related Content
Ana C. Garrido-Castro, MD, a medical oncologist and codirector of the Triple-Negative Breast Cancer Working Group at Dana-Farber Cancer Institute and assistant professor of medicine at Harvard Medical School
June 2nd 2024

Pembrolizumab Plus Sacituzumab Govitecan Shows Nonsignificant Trend Toward Improved PFS in HR+ Breast Cancer

Jefferson Faculty Highlight COVID-19-Induced Disparities in Older Patients With Cancer
June 6th 2022

Jefferson Faculty Highlight COVID-19-Induced Disparities in Older Patients With Cancer

Christian U. Blank, MD, of Netherlands Cancer Institute
June 2nd 2024

Neoadjuvant Nivolumab/Ipilimumab New Standard of Care for Stage III Melanoma

FDA Approval Insights: Relatlimab Plus Nivolumab in Melanoma
May 2nd 2022

FDA Approval Insights: Relatlimab Plus Nivolumab in Melanoma

Atezolizumab plus neoadjuvant pertuzumab, trastuzumab, in HER2-positive early breast cancer.
May 30th 2024

Atezolizumab Elicits Numerical Improvement in 3-Year EFS, DFS in HER2+ Early Breast Cancer

Michiel Van der Heijden, MD, PhD, medical oncologist and research group leader at Netherlands Cancer Institute
May 29th 2024

Frontline Nivolumab/Chemo Approved in Europe for Unresectable or Metastatic Urothelial Cancer